Study summary

A HER2 antibody-drug conjugate shrank tumors in 91.7% of HER2-high salivary cancers

Trastuzumab rezetecan trial · 46 people, phase 2 · Published September 2026, Journal of Clinical Oncology

91.7%response rate in HER2-high disease

What was tested

Trastuzumab rezetecan (SHR-A1811), an antibody that carries chemotherapy directly to HER2-positive cells, in advanced salivary gland carcinoma, with separate HER2-high and HER2-low groups.

What they found

What it means

Suggests HER2 drug conjugates could work even when HER2 levels are only modest.

J Clin Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.